Reviva Pharmaceuticals Holdings Future Growth
Future criteria checks 0/6
Reviva Pharmaceuticals Holdings's earnings are forecast to decline at 4.9% per annum. EPS is expected to grow by 11.2% per annum.
Key information
-4.9%
Earnings growth rate
11.2%
EPS growth rate
Pharmaceuticals earnings growth | 22.9% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely
Aug 24We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Dec 28Reviva Pharmaceuticals drops 9% on $8.5M private placement
Sep 06We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Aug 24Reviva Pharmaceuticals Q2 GAAP loss per share widens
Aug 15Reviva reports positive brilaroxazine results in Aacute Schizophrenia
Apr 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -43 | N/A | -58 | 3 |
12/31/2024 | N/A | -43 | N/A | -58 | 3 |
12/31/2023 | N/A | -39 | -28 | -28 | N/A |
9/30/2023 | N/A | -38 | -24 | -24 | N/A |
6/30/2023 | N/A | -31 | -22 | -22 | N/A |
3/31/2023 | N/A | -24 | -21 | -21 | N/A |
12/31/2022 | N/A | -28 | -19 | -19 | N/A |
9/30/2022 | N/A | -20 | -18 | -18 | N/A |
6/30/2022 | N/A | -19 | -16 | -16 | N/A |
3/31/2022 | N/A | -15 | -14 | -14 | N/A |
12/31/2021 | N/A | -9 | -11 | -11 | N/A |
9/30/2021 | N/A | -6 | -10 | -10 | N/A |
6/30/2021 | N/A | -5 | -8 | -8 | N/A |
3/31/2021 | N/A | -4 | -7 | -7 | N/A |
12/31/2020 | N/A | -4 | -4 | -4 | N/A |
9/30/2020 | N/A | -2 | -1 | -1 | N/A |
6/30/2020 | N/A | -2 | 0 | 0 | N/A |
3/31/2020 | N/A | -1 | 0 | 0 | N/A |
12/31/2019 | N/A | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if RVPH's revenue is forecast to grow faster than the US market.
High Growth Revenue: RVPH is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RVPH's Return on Equity is forecast to be high in 3 years time